Treatment of Retroperitoneal Well-Differentiated Liposarcoma with Combination of Penpulimab and Anlotinib: A Case Report and Literature Review.

To observe the efficacy of combination therapy with Penpulimab and Anlotinib in the treatment of retroperitoneal well-differentiated liposarcoma. Retrospective analysis of clinical data of a patient with retroperitoneal well-differentiated soft tissue sarcoma admitted to Shaoxing People's Hospital, and review of relevant literature. The patient is a young male who experienced recurrence of retroperitoneal well-differentiated liposarcoma after two surgeries. After first-line treatment with Anlotinib combined with Penpulimab, the patient achieved almost complete remission with a progression free survival period of about 16 months. The first-line treatment of retroperitoneal well-differentiated soft tissue sarcoma using Anlotinib combined with Penpulimab resulted in a good prognosis.